Feng S, Chen JK, Yu H, Simon JA, Schreiber SL. Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science. 1994;266(5188):1241-7.
Spencer DM, Graef I, Austin DJ, Schreiber SL, Crabtree GR. A general strategy for producing conditional alleles of Src-like tyrosine kinases. Proc Natl Acad Sci U S A. 1995;92(21):9805-9.
Lee JJ, van de Ven RAH, Zaganjor E, et al. Inhibition of epithelial cell migration and Src/FAK signaling by SIRT3. Proc Natl Acad Sci U S A. 2018;115(27):7057-7062. doi:10.1073/pnas.1800440115
Du J, Bernasconi P, Clauser KR, et al. Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol. 2009;27(1):77-83. doi:10.1038/nbt.1513
Rosenbluh J, Nijhawan D, Cox AG, et al. β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151(7):1457-73. doi:10.1016/j.cell.2012.11.026
Draberova L, Bugajev V, Potuckova L, et al. Transmembrane adaptor protein PAG/CBP is involved in both positive and negative regulation of mast cell signaling. Mol Cell Biol. 2014;34(23):4285-300. doi:10.1128/MCB.00983-14
Park E, Kim N, Ficarro SB, et al. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 2015;22(9):703-11. doi:10.1038/nsmb.3074
Mertins P, Mani DR, Ruggles KV, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55-62. doi:10.1038/nature18003
Georghiou G, Kleiner RE, Pulkoski-Gross M, Liu DR, Seeliger MA. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Nat Chem Biol. 2012;8(4):366-74. doi:10.1038/nchembio.792
Kleiner RE, Dumelin CE, Tiu GC, Sakurai K, Liu DR. In vitro selection of a DNA-templated small-molecule library reveals a class of macrocyclic kinase inhibitors. J Am Chem Soc. 2010;132(33):11779-91. doi:10.1021/ja104903x